Pharmacoeconomic analysis of 3 treatment strategies for cytomegalovirus retinitis in patients with AIDS

Robert I. Griffiths, Giselle C. Bleecker, Douglas Jabs, Douglas T. Dieterich, Laura Coleson, Debbie Winters, Richard Wolitz, Earl P. Steinberg

Research output: Contribution to journalArticle

Abstract

A decision-analytical simulation model was constructed to perform a pharmacoeconomic analysis of the following 3 treatment strategies for previously untreated cytomegalovirus (CMV) retinitis in patients with AIDS: (i) intravenous foscarnet (IVF) for induction and maintenance therapy; (ii) intravenous ganciclovir (IVG) for induction and maintenance therapy; and (iii) intravenous ganciclovir for induction therapy, followed by oral ganciclovir for maintenance therapy (IVG-ORG). Patients who experienced significant adverse effects during, or who failed, initial therapy were switched once to one of the other 2 treatments. The model was used to estimate the direct medical cost (from the perspective of a public payer), survival, and survival adjusted for disutility because of lost vision, for each strategy in the first year following treatment initiation. The expected first-year costs of treatment initiated with IVF, IVG and IVG-ORG were $US47,918, $US38,817 and SUS32,036 (1994 values), respectively, while expected first-year survival was 41 weeks, 35 weeks and 35 weeks, respectively. The incremental cost per incremental year of survival using IVF was $US78,000 versus IVG and $US138,000 versus IVG-ORG before adjustment for lost vision, and $US93,000 versus IVG and $US166,000 versus IVG-ORG after adjustment for lost vision. About 23% of the cost of the IVG treatment strategy was attributable to treatment-related adverse events, compared with 14% of the cost of IVF and 16% of the cost of IVG-ORG. Because of the high failure rate with IVG-ORG, initial treatment with IVG-ORG frequently led to switching to another treatment. Only 27% of the costs associated with the IVG-ORG treatment strategy were in fact attributable to the cost of induction and maintenance therapy prior to a switch to alternative treatment. In this analysis, initial treatment with IVG-ORG was the least costly approach for treating CMV retinitis in patients with AIDS. Initial treatment with IVF resulted in slightly longer survival adjusted for vision-related quality of life. New treatments for AIDS may reduce the survival benefit of initial treatment with IVF.

Original languageEnglish (US)
Pages (from-to)461-474
Number of pages14
JournalPharmacoEconomics
Volume13
Issue number4
DOIs
StatePublished - 1998

Fingerprint

Cytomegalovirus Retinitis
Pharmaceutical Economics
Ganciclovir
Acquired Immunodeficiency Syndrome
Foscarnet
Therapeutics
Costs and Cost Analysis
Survival

ASJC Scopus subject areas

  • Pharmacology
  • Medicine (miscellaneous)

Cite this

Griffiths, R. I., Bleecker, G. C., Jabs, D., Dieterich, D. T., Coleson, L., Winters, D., ... Steinberg, E. P. (1998). Pharmacoeconomic analysis of 3 treatment strategies for cytomegalovirus retinitis in patients with AIDS. PharmacoEconomics, 13(4), 461-474. https://doi.org/10.2165/00019053-199813040-00008

Pharmacoeconomic analysis of 3 treatment strategies for cytomegalovirus retinitis in patients with AIDS. / Griffiths, Robert I.; Bleecker, Giselle C.; Jabs, Douglas; Dieterich, Douglas T.; Coleson, Laura; Winters, Debbie; Wolitz, Richard; Steinberg, Earl P.

In: PharmacoEconomics, Vol. 13, No. 4, 1998, p. 461-474.

Research output: Contribution to journalArticle

Griffiths, RI, Bleecker, GC, Jabs, D, Dieterich, DT, Coleson, L, Winters, D, Wolitz, R & Steinberg, EP 1998, 'Pharmacoeconomic analysis of 3 treatment strategies for cytomegalovirus retinitis in patients with AIDS', PharmacoEconomics, vol. 13, no. 4, pp. 461-474. https://doi.org/10.2165/00019053-199813040-00008
Griffiths, Robert I. ; Bleecker, Giselle C. ; Jabs, Douglas ; Dieterich, Douglas T. ; Coleson, Laura ; Winters, Debbie ; Wolitz, Richard ; Steinberg, Earl P. / Pharmacoeconomic analysis of 3 treatment strategies for cytomegalovirus retinitis in patients with AIDS. In: PharmacoEconomics. 1998 ; Vol. 13, No. 4. pp. 461-474.
@article{c6be42838f6943e3a96801e243d57546,
title = "Pharmacoeconomic analysis of 3 treatment strategies for cytomegalovirus retinitis in patients with AIDS",
abstract = "A decision-analytical simulation model was constructed to perform a pharmacoeconomic analysis of the following 3 treatment strategies for previously untreated cytomegalovirus (CMV) retinitis in patients with AIDS: (i) intravenous foscarnet (IVF) for induction and maintenance therapy; (ii) intravenous ganciclovir (IVG) for induction and maintenance therapy; and (iii) intravenous ganciclovir for induction therapy, followed by oral ganciclovir for maintenance therapy (IVG-ORG). Patients who experienced significant adverse effects during, or who failed, initial therapy were switched once to one of the other 2 treatments. The model was used to estimate the direct medical cost (from the perspective of a public payer), survival, and survival adjusted for disutility because of lost vision, for each strategy in the first year following treatment initiation. The expected first-year costs of treatment initiated with IVF, IVG and IVG-ORG were $US47,918, $US38,817 and SUS32,036 (1994 values), respectively, while expected first-year survival was 41 weeks, 35 weeks and 35 weeks, respectively. The incremental cost per incremental year of survival using IVF was $US78,000 versus IVG and $US138,000 versus IVG-ORG before adjustment for lost vision, and $US93,000 versus IVG and $US166,000 versus IVG-ORG after adjustment for lost vision. About 23{\%} of the cost of the IVG treatment strategy was attributable to treatment-related adverse events, compared with 14{\%} of the cost of IVF and 16{\%} of the cost of IVG-ORG. Because of the high failure rate with IVG-ORG, initial treatment with IVG-ORG frequently led to switching to another treatment. Only 27{\%} of the costs associated with the IVG-ORG treatment strategy were in fact attributable to the cost of induction and maintenance therapy prior to a switch to alternative treatment. In this analysis, initial treatment with IVG-ORG was the least costly approach for treating CMV retinitis in patients with AIDS. Initial treatment with IVF resulted in slightly longer survival adjusted for vision-related quality of life. New treatments for AIDS may reduce the survival benefit of initial treatment with IVF.",
author = "Griffiths, {Robert I.} and Bleecker, {Giselle C.} and Douglas Jabs and Dieterich, {Douglas T.} and Laura Coleson and Debbie Winters and Richard Wolitz and Steinberg, {Earl P.}",
year = "1998",
doi = "10.2165/00019053-199813040-00008",
language = "English (US)",
volume = "13",
pages = "461--474",
journal = "PharmacoEconomics",
issn = "1170-7690",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - Pharmacoeconomic analysis of 3 treatment strategies for cytomegalovirus retinitis in patients with AIDS

AU - Griffiths, Robert I.

AU - Bleecker, Giselle C.

AU - Jabs, Douglas

AU - Dieterich, Douglas T.

AU - Coleson, Laura

AU - Winters, Debbie

AU - Wolitz, Richard

AU - Steinberg, Earl P.

PY - 1998

Y1 - 1998

N2 - A decision-analytical simulation model was constructed to perform a pharmacoeconomic analysis of the following 3 treatment strategies for previously untreated cytomegalovirus (CMV) retinitis in patients with AIDS: (i) intravenous foscarnet (IVF) for induction and maintenance therapy; (ii) intravenous ganciclovir (IVG) for induction and maintenance therapy; and (iii) intravenous ganciclovir for induction therapy, followed by oral ganciclovir for maintenance therapy (IVG-ORG). Patients who experienced significant adverse effects during, or who failed, initial therapy were switched once to one of the other 2 treatments. The model was used to estimate the direct medical cost (from the perspective of a public payer), survival, and survival adjusted for disutility because of lost vision, for each strategy in the first year following treatment initiation. The expected first-year costs of treatment initiated with IVF, IVG and IVG-ORG were $US47,918, $US38,817 and SUS32,036 (1994 values), respectively, while expected first-year survival was 41 weeks, 35 weeks and 35 weeks, respectively. The incremental cost per incremental year of survival using IVF was $US78,000 versus IVG and $US138,000 versus IVG-ORG before adjustment for lost vision, and $US93,000 versus IVG and $US166,000 versus IVG-ORG after adjustment for lost vision. About 23% of the cost of the IVG treatment strategy was attributable to treatment-related adverse events, compared with 14% of the cost of IVF and 16% of the cost of IVG-ORG. Because of the high failure rate with IVG-ORG, initial treatment with IVG-ORG frequently led to switching to another treatment. Only 27% of the costs associated with the IVG-ORG treatment strategy were in fact attributable to the cost of induction and maintenance therapy prior to a switch to alternative treatment. In this analysis, initial treatment with IVG-ORG was the least costly approach for treating CMV retinitis in patients with AIDS. Initial treatment with IVF resulted in slightly longer survival adjusted for vision-related quality of life. New treatments for AIDS may reduce the survival benefit of initial treatment with IVF.

AB - A decision-analytical simulation model was constructed to perform a pharmacoeconomic analysis of the following 3 treatment strategies for previously untreated cytomegalovirus (CMV) retinitis in patients with AIDS: (i) intravenous foscarnet (IVF) for induction and maintenance therapy; (ii) intravenous ganciclovir (IVG) for induction and maintenance therapy; and (iii) intravenous ganciclovir for induction therapy, followed by oral ganciclovir for maintenance therapy (IVG-ORG). Patients who experienced significant adverse effects during, or who failed, initial therapy were switched once to one of the other 2 treatments. The model was used to estimate the direct medical cost (from the perspective of a public payer), survival, and survival adjusted for disutility because of lost vision, for each strategy in the first year following treatment initiation. The expected first-year costs of treatment initiated with IVF, IVG and IVG-ORG were $US47,918, $US38,817 and SUS32,036 (1994 values), respectively, while expected first-year survival was 41 weeks, 35 weeks and 35 weeks, respectively. The incremental cost per incremental year of survival using IVF was $US78,000 versus IVG and $US138,000 versus IVG-ORG before adjustment for lost vision, and $US93,000 versus IVG and $US166,000 versus IVG-ORG after adjustment for lost vision. About 23% of the cost of the IVG treatment strategy was attributable to treatment-related adverse events, compared with 14% of the cost of IVF and 16% of the cost of IVG-ORG. Because of the high failure rate with IVG-ORG, initial treatment with IVG-ORG frequently led to switching to another treatment. Only 27% of the costs associated with the IVG-ORG treatment strategy were in fact attributable to the cost of induction and maintenance therapy prior to a switch to alternative treatment. In this analysis, initial treatment with IVG-ORG was the least costly approach for treating CMV retinitis in patients with AIDS. Initial treatment with IVF resulted in slightly longer survival adjusted for vision-related quality of life. New treatments for AIDS may reduce the survival benefit of initial treatment with IVF.

UR - http://www.scopus.com/inward/record.url?scp=0031887881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031887881&partnerID=8YFLogxK

U2 - 10.2165/00019053-199813040-00008

DO - 10.2165/00019053-199813040-00008

M3 - Article

C2 - 10178669

AN - SCOPUS:0031887881

VL - 13

SP - 461

EP - 474

JO - PharmacoEconomics

JF - PharmacoEconomics

SN - 1170-7690

IS - 4

ER -